QED Therapeutics, a BridgeBio company

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, QED Therapeutics, a BridgeBio company sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 2 currently recruiting 2 completed upper quartile by trial count

QED Therapeutics, a BridgeBio company: 8 sponsored US clinical trials, 2 recruiting.

QED Therapeutics, a BridgeBio company sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 3 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Achondroplasia, with 2 trials.

Upper-quartile sponsor footprint

QED Therapeutics, a BridgeBio company sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 2

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
RECRUITING

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976
ACTIVE NOT RECRUITING

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

NCT04035811
COMPLETED Phase 3

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

NCT06164951
TERMINATED Phase 3

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

NCT04197986
COMPLETED Phase 2

Study of Infigratinib in Children With Achondroplasia

NCT04265651
TERMINATED Phase 3

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

NCT03773302
TERMINATED Phase 2

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

NCT02150967

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 3

Therapeutic Areas

Achondroplasia 2
Hypochondroplasia 1

What is open in the QED Therapeutics, a BridgeBio company pipeline

2 recruiting of 8 indexed (25% open); 2 completed (25%).

Phase mix: 3 late (III/IV) vs 3 early (I/II) (balanced across stages).

Top condition: Achondroplasia (2 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

QED Therapeutics, a BridgeBio company: open-pipeline peers nationwide

Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

QED Therapeutics, a BridgeBio company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%10%20%30%40% Total trials Recruiting share QED Therapeutics, a BridgeBio companyAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Abdul Latif Jameel Poverty Action LabAccutar BiotechnologyAdrienne G. WaksAdvocate Hospital System
QED Therapeutics, a BridgeBio company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

QED Therapeutics, a BridgeBio company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this QED Therapeutics, a BridgeBio company page

8 registered trials is a research-attention snapshot, not an endorsement of QED Therapeutics, a BridgeBio company or any single study.

  • 2 of QED Therapeutics, a BridgeBio company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Achondroplasia is the condition QED Therapeutics, a BridgeBio company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Achondroplasia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

QED Therapeutics, a BridgeBio company pipeline card: 8 registered trials from official public datasets.Report a data error.